Endometrial cancer risk with menopausal hormone therapy: Health Insurance Database in South Korea-based cohort study.

Jin-Sung Yuk

Published in: International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2023)

Tibolone, combined estrogen plus progestin by the physician, and transdermal estrogen do not affect the risk of endometrial cancer. The combination of estrogen plus progestin by the manufacturer decreases the risk of endometrial cancer.

Keyphrases

endometrial cancer
health insurance
estrogen receptor
affordable care act
emergency department
primary care
healthcare
adverse drug
bone marrow